Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32,921 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ; BRIDGE Investigators. Angiolillo DJ, et al. Among authors: liu t. JAMA. 2012 Jan 18;307(3):265-74. doi: 10.1001/jama.2011.2002. JAMA. 2012. PMID: 22253393 Free PMC article. Clinical Trial.
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC. Angiolillo DJ, et al. Among authors: liu t. J Thromb Thrombolysis. 2012 Jul;34(1):44-55. doi: 10.1007/s11239-012-0737-3. J Thromb Thrombolysis. 2012. PMID: 22569899 Clinical Trial.
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
Angiolillo DJ, Bhatt DL, Steg PG, Stone GW, White HD, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Mahaffey KW, Harrington RA. Angiolillo DJ, et al. Among authors: liu t. J Thromb Thrombolysis. 2015 Oct;40(3):317-22. doi: 10.1007/s11239-015-1233-3. J Thromb Thrombolysis. 2015. PMID: 26024789 Clinical Trial.
Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
Firstenberg MS, Dyke CM, Angiolillo DJ, Ramaiahm C, Price M, Brtko M, Welsby I, Chandna H, Holmes DR, Voeltz M, Tummala P, Hutyra M, Manoukian SV, Prats J, Todd M, Liu T, Chronos N, Dietrich M, Montalescot G, Cannon LA, Topo EJ. Firstenberg MS, et al. Among authors: liu t. Heart Surg Forum. 2013 Apr;16(2):E60-9. doi: 10.1532/HSF98.20121103. Heart Surg Forum. 2013. PMID: 23625478 Clinical Trial.
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
Généreux P, Stone GW, Harrington RA, Gibson CM, Steg PG, Brener SJ, Angiolillo DJ, Price MJ, Prats J, LaSalle L, Liu T, Todd M, Skerjanec S, Hamm CW, Mahaffey KW, White HD, Bhatt DL; CHAMPION PHOENIX Investigators. Généreux P, et al. Among authors: liu t. J Am Coll Cardiol. 2014 Feb 25;63(7):619-629. doi: 10.1016/j.jacc.2013.10.022. Epub 2013 Oct 30. J Am Coll Cardiol. 2014. PMID: 24184169 Free article. Clinical Trial.
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
O'Donoghue ML, Bhatt DL, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Deliargyris EN, Mahaffey KW, White HD, Harrington RA; CHAMPION PHOENIX Investigators. O'Donoghue ML, et al. Among authors: liu t. Circulation. 2016 Jan 19;133(3):248-55. doi: 10.1161/CIRCULATIONAHA.115.017300. Circulation. 2016. PMID: 26762525 Free PMC article. Clinical Trial.
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
White HD, Bhatt DL, Gibson CM, Hamm CW, Mahaffey KW, Price MJ, Steg PG, Stone GW, Cortese B, Wilensky M, Deliargyris EN, Liu T, Prats J, Harrington RA. White HD, et al. Among authors: liu t. JACC Cardiovasc Interv. 2015 Mar;8(3):424-433. doi: 10.1016/j.jcin.2014.09.025. Epub 2015 Feb 18. JACC Cardiovasc Interv. 2015. PMID: 25703887 Free article. Clinical Trial.
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators. Bhatt DL, et al. Among authors: liu t. N Engl J Med. 2013 Apr 4;368(14):1303-13. doi: 10.1056/NEJMoa1300815. Epub 2013 Mar 10. N Engl J Med. 2013. PMID: 23473369 Free article. Clinical Trial.
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA; CHAMPION Investigators. Steg PG, et al. Among authors: liu t. Lancet. 2013 Dec 14;382(9909):1981-92. doi: 10.1016/S0140-6736(13)61615-3. Epub 2013 Sep 3. Lancet. 2013. PMID: 24011551
32,921 results
You have reached the last available page of results. Please see the User Guide for more information.